From a developing country perspective, this study explains the factors affecting online learning amidst the COVID-19 pandemic. The paper empirically tests the proposed extended unified theory of acceptance and use of technology (E-UTAUT) model in the students' intention and use behavior towards the online learning system. Understanding the acceptance of online learning technology is crucial, especially among developing countries caught off-guard by the abrupt transition of face-to-face classes to pure online learning. The enjoyment, interactivity, flexibility, and quality of online learning systems were added as antecedent variables to the UTAUT model. Eight hundred eighty valid responses from selected college students in the Visayas regions, Philippines, were collected. Structural equation modeling (SEM) was employed to verify the research hypotheses. The results supported the proposed model with acceptable fit measures and substantial explanatory power. The extended constructs pr
In the last few decades, the world has faced some natural issues, due to which economic growth faces a severe threat. Natural disasters like pandemic outbreaks and man-made disasters like pollution emissions are very frequent in the current times, which also influenced the economic growth, where the institutes could play a primary role in economic growth stimulation. This study aims to analyze the association of public health expenditures, institutional quality, renewable energy, and economic performance in China. This study uses quarterly data covering the period from 1996Q1 to 2020Q4 and employs various time-series estimating approaches. The Augmented Dickey-Fuller estimates asserted that all the variables are stationary at first difference. Also, the Bayer-Hanck combined cointegration validates that all the variables are cointegrated. Employing the three long-run estimators, i.e., Fully Modified Ordinary Least Square, Dynamic Ordinary Least Square, and canonical cointegrating regres
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy. Saphnelo is the first biologic for SLE approved in .
Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosusSaphnelo is a first-in-class type I interferon receptor antibody and the only new medicine in over a decade for patients with systemic lupus erythematosusAstraZeneca’s Saphnelo (anifrolumab) has been approved in the.